X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
IRL790 (mesdopetam) is an investigational drug, a dopamine D3 receptor antagonist which is under phase 2 clinical development for the treatment of Parkinson's disease levodopa-induced dyskinesias (PD-LIDs).
Lead Product(s): Mesdopetam
Therapeutic Area: Neurology Product Name: IRL790
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2024
Details:
IRL790 (mesdopetam), a dopamine D3 receptor antagonist, is being developed as a treatment for Parkinson's disease levodopa-induced dyskinesias (PD-LIDs).
Lead Product(s): Mesdopetam
Therapeutic Area: Neurology Product Name: IRL790
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Details:
IRL790 (mesdopetam) is an investigational drug, a dopamine D3 receptor antagonist which is under phase 2 clinical development for the treatment of Parkinson's disease levodopa-induced dyskinesias (PD-LIDs).
Lead Product(s): Mesdopetam
Therapeutic Area: Neurology Product Name: IRL790
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
The financing will be used for the advancement of IRL790 (mesdopetam), in development for the treatment of levodopa-induced dyskinesias, which has completed Phase IIb and is in preparation toward Phase III.
Lead Product(s): Mesdopetam
Therapeutic Area: Neurology Product Name: IRL790
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Formue Nord Fokus
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing December 22, 2023
Details:
IRL790 (mesdopetam) is an investigational drug, a dopamine D3 receptor antagonist which is under phase 2 clinical development for the treatment of Parkinson's disease levodopa-induced dyskinesias (PD-LIDs).
Lead Product(s): Mesdopetam
Therapeutic Area: Neurology Product Name: IRL790
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
IRL790 (mesdopetam), a dopamine D3 receptor antagonist, which is investigated for the treatment of Parkinson's disease levodopa-induced dyskinesias (PD-LIDs).
Lead Product(s): Mesdopetam
Therapeutic Area: Neurology Product Name: IRL790
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2023
Details:
Under the agreement, IRLAB secured full ownership rights for the now Phase III-ready IRL790 (mesdopetam), a dopamine D3 receptor antagonist, in development as a treatment of Parkinson's disease levodopa-induced dyskinesias.
Lead Product(s): Mesdopetam
Therapeutic Area: Neurology Product Name: IRL790
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: IRLAB
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 21, 2023
Details:
IRL790 (mesdopetam), a dopamine D3 receptor antagonist, which is investigated for the treatment of Parkinson's disease levodopa-induced dyskinesias (PD-LIDs).
Lead Product(s): Mesdopetam
Therapeutic Area: Neurology Product Name: IRL790
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 21, 2023
Details:
IRL790 (mesdopetam) is an oral dopamine D3-receptor antagonist being developed for the treatment of levodopa-induced dyskinesias (LIDs), a severe form of troublesome involuntary movements commonly occurring in Parkinson’s disease.
Lead Product(s): Mesdopetam
Therapeutic Area: Neurology Product Name: IRL790
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Details:
Mesdopetam (IRL790), an oral dopamine D3 antagonist, is being developed in partnership with Ipsen as a treatment for Parkinson's disease levodopa-induced dyskinesias (PD-LIDs), a severe form of troublesome involuntary movements commonly occurring in Parkinson's disease.
Lead Product(s): Mesdopetam
Therapeutic Area: Neurology Product Name: IRL790
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2022
Details:
Mesdopetam (IRL790) is a novel dopamine D3 receptor antagonist developed for the management of complications of therapy in PD, was well-tolerated up to a 120 mg single dose and up to 80 mg upon multiple dosing.
Lead Product(s): Mesdopetam
Therapeutic Area: Neurology Product Name: IRL790
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2022
Details:
Mesdopetam (IRL790) is a dopamine D3-receptor antagonist being developed for the treatment of levodopa-induced dyskinesias (LIDs), a severe form of troublesome involuntary movements commonly occurring in Parkinson's disease.
Lead Product(s): Mesdopetam
Therapeutic Area: Neurology Product Name: IRL790
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
Details:
Mesdopetam (IRL790) is a dopamine D3-receptor antagonist being developed for the treatment of levodopa-induced dyskinesias (LIDs), a severe form of troublesome involuntary movements commonly occurring in Parkinson's disease.
Lead Product(s): Mesdopetam
Therapeutic Area: Neurology Product Name: IRL790
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: IRLAB
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2022
Details:
This new published patent application relates, inter alia, to a new salt of mesdopetam that is intended to be included in the final pharmaceutical product.
Lead Product(s): Mesdopetam
Therapeutic Area: Neurology Product Name: IRL790
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2020
Details:
The acceptance of the IND will allow IRLAB to include US patients in the upcoming clinical trial in Parkinson’s disease in accordance with the study protocol. The planned Phase IIb/III study for mesdopetam will thus include hospitals and enrol patients in the US and Europe.
Lead Product(s): Mesdopetam
Therapeutic Area: Neurology Product Name: IRL790
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 01, 2020
Details:
When mesdopetam was given in addition to standard Parkinson medication, patients experienced considerably longer periods of good daily motor function without aggravated involuntary movements.
Lead Product(s): Mesdopetam
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2020
Details:
WHO concluded that IRL790 is wholly unique in its mechanism of action and has, therefore, given IRL790 a new INN.
Lead Product(s): Mesdopetam
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
